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ABSTRACT
Since numerous miRNAs have been shown to be present in circulation, these so-called circulating miRNAs have emerged as
potential biomarkers for disease. However, results of qPCR studies on circulating miRNA biomarkers vary greatly and many
experiments cannot be reproduced. Missing data in qPCR experiments often occur due to off-target amplification,
nonanalyzable qPCR curves and discordance between replicates. The low concentration of most miRNAs leads to most, but
not all missing data. Therefore, failure to distinguish between missing data due to a low concentration and missing data due to
randomly occurring technical errors partly explains the variation within and between otherwise similar studies. Based on qPCR
kinetics, an analysis pipeline was developed to distinguish missing data due to technical errors from missing data due to a low
concentration of the miRNA-equivalent cDNA in the PCR reaction. Furthermore, this pipeline incorporates a method to
statistically decide whether concentrations from replicates are sufficiently concordant, which improves stability of results and
avoids unnecessary data loss. By going through the pipeline’s steps, the result of each measurement is categorized as “valid,
invalid, or undetectable.” Together with a set of imputation rules, the pipeline leads to more robust and reproducible data as
was confirmed experimentally. Using two validation approaches, in two cohorts totaling 2214 heart failure patients, we
showed that this pipeline increases both the accuracy and precision of qPCR measurements. In conclusion, this statistical data
handling pipeline improves the performance of qPCR studies on low-expressed targets such as circulating miRNAs.
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INTRODUCTION
MiRNAs are small noncoding RNA molecules that bind to
target mRNAs and thereby inhibit their translation into a
protein (Bartel 2004). The presence of miRNAs in circulation
makes them easily accessible and consequently they have
emerged as a novel class of biomarkers for a wide range of dis-
eases, including cardiovascular diseases (Gilad et al. 2008;
Tijsen et al. 2012; Romaine et al. 2015). However, studies
on circulating miRNAs show very low reproducibility. A re-
cent review of 11 similar studies, together identifying 31 heart
failure-related miRNAs, showed that only five of these
miRNAs could be reproduced in more than one study and
that none could be reproduced in more than two studies
(Romaine et al. 2015).
MiRNA biomarker identification often starts with a high-
throughput screen (e.g., microarray), after which the most
promising candidates are validated by quantitative polymer-
ase chain reaction (qPCR) measurements. Despite the fact
that qPCR is a sensitive method, challenges arise when work-
ing with target quantities near the detection limit of qPCR, as
is the case for many circulating miRNAs. This leads to miss-
ing data, which is handled and interpreted differently be-
tween studies, leading to differences in outcome.
To date, there is no consensus on how to handle missing
data in qPCR studies in a statistically valid manner.
Therefore, we propose an analysis pipeline to standardize
Abbreviations: N0, starting concentration; Cq, quantification cycle (i.e., the
fractional cycle at which the fluorescence of the amplification product reach-
es the quantification threshold).
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the handling of results in low-target quantity qPCR experi-
ments, such as in the case of circulating miRNAs, to assure
statistical validity and improve reproducibility.
Occurrence of missing data in qPCR results
Quantitative PCR is a sensitive method to quantitatively as-
sess miRNA levels (Zampetaki and Mayr 2012). The real-
time monitoring of the fluorescence associated with the
amplification of cDNA derived from specific miRNA species
(Gibson et al. 1996) results in an amplification curve. There
are various software packages to analyze the qPCR curve, re-
sulting in a quantification cycle (Cq) or, using an estimate of
the amplification efficiency value to perform the calculation,
in a starting concentration (N0) (Ruijter et al. 2013).
Before theCq orN0 values can be used in the statistical anal-
ysis of the experiment, their validity has to be ascertained.
Firstly, a check that the correct product is amplified has to
be carried out. Some monitoring chemistries allow a melting
curve analysis for this purpose; otherwise gel electrophoresis
is an option. When an off-target product is amplified, Cq or
N0 values have to be set to missing. Next, the quality of the
amplification curves should be sufficient to allow analysis.
Several methods are available to perform such a quality con-
trol (Bar et al. 2003; Ruijter et al. 2009; Sisti et al. 2010;
Tichopad et al. 2010). In general, to allow analysis of amplifi-
cation curves, these curves should at least consist of an expo-
nential phase and a plateau phase. If not, the curve analysis
software rules out these reactions and marks the results as
missing. The absence of amplification or the absence of a pla-
teau phase most often indicates that the template concentra-
tion was under the detection limit of the qPCR assay.
However, deviating amplification curves do not just occur at
low concentrations and, therefore, some require a different
missing data handling. Finally, results are often set to missing
when there is a large difference in Cq values between replicate
reactions. Although such discordant replicates are mostly
considered to be due to technical variation or pipetting errors,
the Poisson effect that occurs by chance when pipetting from
the cDNA stock to the reaction plate cannot be ignored.
RESULTS
Both imputation and exclusion of all missing data
leads to analysis bias
Since it is known that circulating miRNAs can occur in low
concentrations or might even be totally absent from circula-
tion, a large number of missing values can be expected.
Furthermore, it is known that with decreasing concentration
of the target, the chance of finding a so-called nondetect in-
creases (McCall et al. 2014). This is confirmed in our own
qPCR experiments, which show that among a total of
10,008 qPCR results on 12 different miRNAs from cohort
I, low concentrations (high Cq) of the measured miRNAs re-
sult in more measurements with missing values (Fig. 1).
Missing data can be handled in different ways. Total exclu-
sion of missing data leads to loss of data points and thus to
loss of statistical power. The common practice is therefore
to substitute a missing value with aCq value equal to the max-
imum number of cycles run on the PCR machine. However,
this method sets the N0 to an impossibly low value (McCall
et al. 2014). Moreover, generally, only the curves that cannot
be analyzed are substituted with this low value, while also the
number of reactions with off-target amplification and the
number of discordant replicates increase with a decreasing
input concentration (Fig. 1). As described in detail in
Materials and Methods, multiple imputation can be applied
to replace the missing values with estimates based on patient
characteristics. These imputed values are thus estimated from
the distribution of values that were high enough to be mea-
sured. However, such an imputation ignores the fact that
some missing data are truly zero. Therefore, multiple impu-
tations of all missing values will wrongly increase the average
outcome. To handle missing data correctly, it should be dis-
tinguished and divided into two categories: (i) missing data
that represent an “undetectable” value because the concen-
tration of the target in the sample is either a true zero or
too low to be measured quantitatively, and (ii) “invalid” val-
ues that are missing due to a technical failure and thus repre-
sent true missing values (missing at random).
Minimizing loss of data due to imprecision in replicates
qPCR data are commonly analyzed by calculating the mean
of the results of replicate reactions to reduce the effects of
FIGURE 1. Fraction of measurements that resulted in missing data
from a total of 10,008 qPCR results to measure the expression of 12 dif-
ferent miRNAs (from cohort I). Data are considered missing when one
of the replicate reactions (i) has off-target amplification, (ii) has an am-
plification curve that did not pass the qPCR curve quality control (non-
analyzable curve), or (iii) when the two replicates are more than 0.5
cycles apart, which is more than can be expected from pipetting error
(discordance between replicates). All categories and thus the total num-
ber of missing data increases with increasing Cq value and thus lower in-
put concentration.
de Ronde et al.
812 RNA, Vol. 23, No. 5
technical variation. Unfortunately, missing data and dis-
cordance can occur among replicates. During the experi-
ment, only a small amount of cDNA (usually 1 µL) is
pipetted from the stock to the qPCR plate. Therefore, var-
iation can occur due to pipetting error. A rule of thumb is
that when the variation between replicate Cq values is more
than 0.5 cycles, the data cannot be trusted, and both repli-
cates should be discarded (Nolan et al. 2006). As shown in
Figure 2A, this 0.5 cycles difference is to be expected when
there is ∼15% pipetting error and the template is present at
a high concentration. However, pipetting is a random sam-
pling action and its result will, therefore, always follow a
Poisson distribution (Altman 1990). This means that at
low target concentrations, the variation due to the
Poisson effect becomes larger than the pipetting error and
unavoidably a relatively large range of Cq values will be
found, even with highly skilled operators (Fig. 2B).
Consequently, when working at low concentrations, many
measurements will be discarded unnecessarily, causing
loss of statistical power, when the 0.5 cycles rule is strictly
adhered to.
Handling missing data
In conclusion, missing data can occur from off-target ampli-
fication, nonanalyzable amplification curves, and discord-
ance between replicates. Because the majority, but not all
missing data arise as a result from a low concentration of
the target (Fig. 1), missing data due to low concentration
must be distinguished from data missing at random. Here
we propose a practical analysis pipeline to classify missing
data from qPCR experiments into two categories: invalid
and undetectable measurements, and to handle them accord-
ingly to improve qPCR accuracy and precision.
Data handling pipeline
We propose a data handling pipeline that deals with the above
described issues (Fig. 3). This pipeline consists of four steps
to categorize the results of the qPCR analysis in valid, invalid,
and undetectable and handles those categories accordingly. A
documented SPSS and R syntax, for practical use of the data
handling pipeline and an example of the required data for-
mat, are available for download at http://www.hfrc.nl.
Step 1: Curve analysis
The first step in the pipeline is analysis of the reaction, con-
sisting of confirmation of the correct product and evalua-
tion of the amplification curve quality. Confirmation of
the correct product is done by a manual melting curve anal-
ysis. Note that when hydrolysis probe assays (e.g., Taqman)
are used, melting curve analysis is not required; a validated
probe assay implies that only the correct amplification
product results in fluorescence. In this case, one can start
at step 2 (or at “rank ABC” in the case of triplicates).
Amplification curve quality control can be done by hand
or can be performed by a qPCR curve analysis program
such as LinRegPCR (Ruijter et al. 2009). When off-target
amplification occurs or when the amplification curve can-
not be analyzed, the observed Cq value can never be
converted into a reliable, valid N0. However, off-target am-
plification can occur due to a low target concentration.
Therefore, when a deviating melting peak is observed, the
categorization into invalid or undetectable of the result de-
pends on the Cq value of the associated amplification curve,
and one must proceed to step 3 to handle the reaction based
on the mean Cq of the replicates. When triplicate reactions
are run and only one out of three shows off-target amplifi-
cation, this one replicate must be discarded and one can
proceed through the steps using the oth-
er two replicates.
Step 2: Handling replicate measurements
Most qPCR reactions are conducted as
replicates. To avoid unnecessary loss of
data points (discarding all replicates
with >0.5 cycles difference), as discussed
above, we used the Poisson distribution
to calculate the acceptable Cq range be-
tween replicate measurements for differ-
ent template numbers in the reaction.
The acceptable Cq range is defined as
the interval in which 95% of the Cq val-
ues are expected to be found, given a
certain Cq value (Table 1; Fig. 2B; details
on the calculations are described in cal-
culation 2 in Materials and Methods).
We propose that whenever the replicates
are within this acceptable range, the
FIGURE 2. Sources of variation in observed Cq values between replicates. (A) Relation between
pipetting error and Cq range between replicate measurements. A pipetting error of 15% leads to a
range of 0.5 between replicates. Red line represents the Cq of the pipetting error down and blue
line represents the Cq of the pipetting error up. Orange arrow indicates where the 0.5 cycles be-
tween replicates is expected, which is at 15% pipetting error. For the calculations behind this fig-
ure, see calculation 1 in Materials and Methods. (B) The maximum acceptable Cq difference
between replicates increases with increasing mean Cq of the replicates (lower copy number input
in the reaction) and is dependent on the PCR efficiency. Note that in the graph, 0.5 cycles is con-
sidered to be the maximum allowable Cq range for Cq values where pipetting error is the prevalent
cause of variation. For the calculations behind this figure, see calculation 2 in Materials and
Methods.
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mean of the Cq or therefrom calculated N0 values can be
used in the analysis. If the replicates are not in range, it is
not possible to determine accurately which of the replicate
measurements is correct and therefore there is no reliable
result. In the case of triplicates, it can happen that two rep-
licates are in range of each other and the third replicate is
an outlier. Then, the former replicates are most likely the
accurate ones and one can proceed using only these two
replicates. Therefore, with triplicates, replicates A, B, and
C must be ranked from lowest to highest Cq.
Step 3: Reactions with a Cq value above 35 are
considered too low to be quantitatively measured
(undetectable)
When the concentration of a miRNA is very low, there are
two possible options, either the concentration is too low to
result in detectable amplification, resulting in a missing Cq
value set by the analysis program, or the concentration is
just high enough to give amplification, resulting in amplifica-
tion with a high Cq value. However, such high Cq values often
result from amplification curves that do not reach the plateau
phase, because the number of cycles is limited by the user.
Therefore, above a critical Cq value, reactions should be con-
sidered to have an input that is too low to be reliably quanti-
tatively measured. Note, however, that in a qualitative
diagnostic assay, such reactions should be reported as positive
because the correct product was amplified.
We propose to set the critical Cq value at 35 cycles. This is
the Cq value resulting from an input of approximately 10
copies of template in the reaction (Shipley 2013). This obser-
vation comes from general experience and is supported by an
easy calculation (see calculation 3 in Materials andMethods),
which shows that an optimal qPCR with a primer concentra-
tion of 1 µmol/L and 10 template molecules in a reaction,
reaches the end of the exponential phase after approximately
35 cycles where amplicon and primer concentrations become
similar (Gevertz et al. 2005). Moreover, the Poisson effect
that occurs when an average of 10 copies of template are pi-
petted from stock to the reaction plate leads to a coefficient of
variation of ∼30%. This means that above a Cq of 35 there
is too much random variation for reliable quantification.
FIGURE 3. Flow diagram of the data handling pipeline for duplicate and triplicate measurements. An extensive description of the pipeline is given in
the Results. Briefly, in step 1, melting and amplification curve analysis is performed by the user. In step 2, the ΔCq of the replicates must be evaluated to
check if they are in the allowed range of each other (for the maximal acceptable range between replicates, see Table 1). Then, based on a critical Cq
value, in step 3, each measurement is categorized as valid, invalid, or undetectable and is handled accordingly. (∗) For most PCR machines and ex-
periments, a critical value of 35 will be optimal; however, this critical Cq may be changed by the user if inappropriate for the experiment. (†) When
using triplicates and all reactions are OK, replicates A, B, and C must be ranked based from lowest to highest Cq. This step avoids discarding all rep-
licates when two out of three are in range of each other and can therefore still be used in the analysis. (‡) A Cq of zero (no amplification) must be
considered the same as having a Cq > 35. qPC = qPCR curve.
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Therefore, all reactions that have a Cq value of more than 35,
and those marked as “no amplification” (Cq of 0), are consid-
ered to contain an undetectable amount of template. Note
that for this pipeline to work, the number of cycles that are
run on the PCR machine should be high enough to reach a
Cq of 35. Therefore, we propose to set the number of PCR cy-
cles on the machine to at least 45 cycles. Although for most
PCR machines and experiments a critical value of 35 will
be optimal, the number of cycles that is needed to reach
the quantification threshold when starting with 10 copies
in the reaction can differ between experiments. There are var-
ious factors of data processing known that can influence the
observed Cq value and can affect the assumed relation be-
tween an input of 10 copies and a Cq of 35. These factors
are (i) preprocessing of the fluorescence data, such as curve
smoothing (Spiess et al. 2015); (ii) the applied monitoring
chemistries, probe types, and platforms (Ruijter et al.
2014); (iii) the method of determining the Cq value
(Ruijter et al. 2013). The critical Cq of 35 may therefore
have to be changed by the user.
Step 4: Handling missing data and normalization
After following the above protocol, the resulting data set con-
sists of valid expression values, invalid values, which aremiss-
ing values at random due to technical error, and undetectable
values, which are missing due to low target input.
Handling invalid values: Because invalid measurements
occur at low Cq values, the technical or biological replicates
of these measurements are valid values in the data set.
Consequently, invalid values can easily be imputed. The ap-
plied imputation method should be multiple imputation,
since most of the variation in a qPCR experiment is caused
by differences at the interindividuals level (Kitchen et al.
2010). The multiple imputation method renders the best es-
timate of that specific miRNA concentration based on all var-
iables that underlie the observed differences in the data set
(Sinharay et al. 2001). It was shown that with multiple impu-
tation, in some cases up to 80% of the missing data can be
reliably imputed (Souverein et al. 2006).
This means that even when there is a
large number of invalid data, their impu-
tation will generally not alter the medi-
cal or biological conclusions of the
experiment.
Handling undetectable values: Debate
exists on what is the best method for sub-
stitution of undetectable values. Since the
qPCR detection limit is variable between
experiments and targets, we propose to
look up the highest Cq for every mea-
sured miRNA. That value represents the
lowest observed miRNA input that pro-
duces an analyzable result. Then, to sub-
stitute the undetectable value, the N0 can
be calculated from this Cq +1. This leaves all undetectable re-
sults for every measured miRNA with low value, adjusted for
target and experiment properties.
After the imputation and substitution steps for invalid and
undetectable values, respectively, the data are log-trans-
formed, to account for the non-normal distribution, and
normalized, to correct for differences in RNA extraction,
RT reaction yield, and sample composition. Normalization
is a prerequisite for accurate qPCR expression profiling and
lack of valid normalization can have a large effect on the
results (Vandesompele et al. 2002). Presently, there is no con-
sensus on the method of normalization of miRNA qPCR re-
sults and several methods have been proposed, among which
are exogenous and endogenous reference targets. Reference
genes can be selected by following a workflow such as that
proposed in the review of Schwarzenbach et al. (2015) or
Marabita et al. (2016). Using a similar workflow, we recently
identified and validated blood product specific normalization
panels consisting of the most stable endogenous miRNAs and
showed that these panels are preferred over other normaliza-
tion methods (Kok et al. 2015). We recommend using these
panels for normalization.
Validation of the proposed pipeline
Improving biomarker precision
When performing two separate qPCR experiments that mea-
sure the same predictor and outcome, results are expected to
be similar. However, similar results can only be obtained
when the qPCR results are precise enough. To determine
the effect of the proposed data handling pipeline on preci-
sion, we validated the data handling pipeline in two large co-
horts (n = 834 and n = 1380, respectively) of heart failure
patients. MiRNAs were measured by qPCR and analyzed
with and without the proposed pipeline. In the analysis with-
out the pipeline, all data that showed off-target amplifica-
tion, nonanalyzable curves and discordance between
replicates were excluded. Cox regression was used to assess
TABLE 1. Maximal acceptable range in replicates is dependent on the mean Cq value
Mean Cq of replicates
PCR efficiency 25 26 27 28 29 30 31 32 33 34 35
1.6 0.5 0.5 0.5 0.5 0.7 0.8 1.1 1.4 1.7 2.2 2.9
1.7 0.5 0.5 0.5 0.5 0.5 0.6 0.8 1.1 1.5 1.9 2.5
1.8 0.5 0.5 0.5 0.5 0.5 0.5 0.7 0.9 1.2 1.7 2.3
1.9 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.8 1.1 1.5 2.1
2.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.7 0.9 1.3 1.9
The numbers are the maximal acceptable differences in quantification cycle (Cq) between
the results of replicate measurements (minimum values set to 0.5). Note that the range
depends on the PCR efficiency value and the mean of the Cq values of the replicates. See
Materials and Methods (calculation 2) for detailed description of the derivation of the equa-
tion to calculate the expected Cq range due to Poisson sampling during pipetting.
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the prognostic value of 12 heart failure-related miRNAs on
mortality and morbidity. When using the analysis pipeline,
the 95% confidence intervals around the HRs were much
tighter (Fig. 4A) than without the analysis pipeline (Fig.
4B), indicating that the HRs were more reliably determined.
More importantly, the ratios of the HRs between cohort I
and cohort II were lower and closer to 1 when the pipeline
was applied, indicating more reproducible results between
cohorts (Fig. 4C). This was especially true for low-expression
miRNAs such as miR-208a-3p and miR133a-3p. As men-
tioned in the Introduction, results from many similar studies
on circulating miRNAs are reported to be highly divergent
(Romaine et al. 2015). The more consistent results between
two cohorts for almost all candidate miRNAs, therefore, in-
dicate that precision is increased when using the data han-
dling pipeline.
Improving biomarker accuracy
We conducted a second validation experiment to investigate
the accuracy of the results after application of the proposed
pipeline. Previous studies showed that miR-499a-5p is upre-
gulated in plasma when the myocardium is damaged
(Corsten et al. 2010). Therefore, we analyzed the relation
between miR-499a-5p expression and the expression of
hs-troponin T (another accepted marker of myocardial
damage) in a large cohort of 834 cases of heart failure.
We hypothesized that the two markers are correlated and
thus we investigated the differences in miR-499a-5p expres-
sion among quartiles of hs-troponin T expression. Heart
failure patients do not have acute and extensive myocardial
damage and therefore their miR-499a-5p expression is low
and differences in miRNA expression are subtle. These
properties are both needed for an optimal test performance
of the pipeline.
We compared five different scenarios of qPCR data han-
dling. In analysis A (Fig. 5A), all measurements that resulted
in missing values were excluded. In analysis B (Fig. 5B),
missing values due to nonanalyzable curves were set to the
number of cycles in the qPCR run, which may lead to unre-
alistically low N0s. In analysis C (Fig. 5C), data were handled
with the pipeline for categorization of missing data, and then
invalid data were replaced by multiple imputation, but the
undetectable values were set to the number of cycles in the
run. Further effects of multiple imputation were tested in
analysis D (Fig. 5D), in which invalid results were excluded
from the analysis and undetectable results were set to one cy-
cle above the maximum reliable Cq found for the miRNA. In
analysis E (Fig. 5E), the complete missing data handling pipe-
line was implemented.
We found higher levels of miR-499a-5p with increasing
hs-troponin T in all the analyses; however, both analyses
without the pipeline (Fig. 5A,B) resulted in considerable
loss of data and, therefore, no significant differences between
miRNA-499a-5p levels between hs-troponin T quartiles were
observed. Analysis of variance and F-tests (Supplemental
FIGURE 4. Analysis of data with and without the pipeline. The graph shows the 95% confidence intervals (CIs) around the hazard ratios (HRs) of 12
miRNAs for the prediction of cardiovascular events when the data are (A) handled with and (B) without the proposed data handling pipeline in both
cohort I (blue whiskers) and cohort II (red whiskers). The bars in panel C show the ratios between the HRs of both cohorts for each miRNA. Because
the cohorts measure the same outcome, a ratio close to 1 is expected. Panel C shows that this is true for most miRNAs when data are analyzed with the
pipeline (orange bars); analysis without the pipeline (gray bars) results in large differences between cohorts.
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Table 1), however, showed smaller variances in analyses A
and B compared with the analysis with the pipeline. This is
due to the selective exclusion of all reactions that resulted
in low values; although seemingly more precise, these results
are highly inaccurate.
Using the pipeline, 77% (n = 641) of the data discarded
in analyses A and B could be “saved” and included in the
analysis that resulted in more narrow 95% confidence in-
tervals. However, setting undetectable results to the number
of cycles in the run (Fig. 5C) showed significantly higher
variances in all quartiles (Supplemental Table 1). Thus,
substitution of undetectable values with impossibly low
N0’s leads to imprecise results. Both analysis D and the
complete pipeline, analysis E, resulted in similar variances
(Supplemental Table 1). However, due to the exclusion of
invalid values, instead of imputation, analysis D (Fig. 5D)
lacked statistical power, which increased the 95% confi-
dence intervals and, therefore, the significant difference be-
tween the first and the second quartile was lost. Only the
complete pipeline (Fig. 5E) showed a significant difference
in miR-499a-5p expression between the first and all other
quartiles, hereby showing the best accuracy in detecting
myocardial damage.
DISCUSSION
We propose a pipeline to handle missing values resulting
from qPCR-based measurements of circulating miRNAs,
based on data that can be obtained by all available qPCR plat-
forms and technologies. Missing values can be the result of
technical errors, but are most often due to template levels
that are too low to measure reliably with qPCR. Exclusion
as well as wrong imputation methods of these missing values
can lead to false analysis results. We show that missing values
due to low concentrations can be distinguished frommissing
data due to technical errors by setting a critical value at aCq of
35 and considering higher Cq values as true undetectable val-
ues. Furthermore, we show that with lower template concen-
trations, large differences between replicate measurements
can be expected to occur. Therefore, these larger differences
between replicates should be accepted in the analysis. Using
these statistical rules, we propose a protocol on how qPCR
data should be handled and we demonstrate that this pipeline
indeed increases precision as well as accuracy in qPCR mea-
surements of circulating miRNAs.
This data handling pipeline is important for reliable mea-
surements on miRNAs by qPCR. Firstly, the pipeline
FIGURE 5. Relation betweenmiR-499a-5p expression and quartiles of hs-troponin T expression. MiR-499a-5p expression is given as normalized and
log-transformed arbitrary fluorescence units. Results are given as mean (dots) with 95% CI around the mean (whiskers). Panels A and B show the use
of a standard method for data analysis in which all missing values are excluded (A) or discordant duplicates and bad melting curves are excluded
but nonanalyzable curves are set to the number of cycles in the qPCR run (B). Consequently, only a small fraction of the data can be used for analysis
(n = 193 and n = 195 in analyses A and B, respectively). Panels C, D, and E show the analysis using the data handling pipeline described in this
article. In panel C the undetectable category is set to the number of cycles in the qPCR run and the invalid category is imputed using multiple im-
putation (n = 834); in panelD the undetectable category is set to the highest reliable Cq +1 and the invalid category is excluded (n = 642); and in panel
E the undetectable category is set to the highest reliable Cq +1 and the invalid category is imputed using multiple imputation (completely according to
the proposed pipeline; n = 834). (∗) P < 0.05 compared with the first quartile.
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prevents misclassification of undetectable values and values
missing at random, thus avoiding the introduction of bias
due to inappropriate substitution or imputation. Subse-
quently, since many circulating miRNAs have a very low con-
centration, the large measurement error due to random
sampling is taken into account to avoid unnecessary discard-
ing of data. At the same time the pipelinemakes sure that only
accurate data are used. Furthermore, our proposedmethod to
handle the difference between the replicates based on their
mean Cq and the associated expected Cq range, retains the
maximum number of valid data while preserving quantitative
accuracy. Thereby, we managed to save 77% of the data that
would have been excluded without the analysis pipeline.
Although a multitude of publications describe how to per-
form qPCR experiments (Zhao and Fernald 2005; Nolan
et al. 2006; VanGuilder et al. 2008; Zampetaki and Mayr
2012), this is the first article that proposes a standardized pro-
tocol on how to handle so-called missing data in the analysis
of qPCR measurements. This is of importance, since the way
these data are handled is diverse between researchers and
largely determines the data used in, and therefore the
outcome of, the statistical analysis of experiments. Nonethe-
less, the data processing is rarely described in articles, and this
omission may explain part of the irreproducibility of results
in miRNA and other qPCR studies. Our results show that
the proposed pipeline can contribute to more reliable and
more reproducible results.
In this study, we only addressed miRNA data. However,
since this protocol is based on the qPCR kinetics that apply
to DNA as well as cDNA, reverse transcribed from mRNA,
it is highly likely that this protocol will benefit all types of
qPCR measurements, especially those with low expression
levels.
Conclusions
We show that a pipeline for handling missing data in qPCR
experiments contributes to more reliable and reproducible
qPCR results when measuring circulating miRNAs. We pro-
pose to use this data handling protocol as a standard for
qPCR experiments in general.
MATERIALS AND METHODS
Definitions
Off-target amplification is defined as amplification that, in the melt-
ing curve analysis, shows a melting peak at a different melting tem-
perature than the positive control or a melting curve that shows
multiple melting peaks. A nonanalyzable amplification curve is de-
fined as an amplification curve that does not meet the quality criteria
of the qPCR curve software. In this study, the curve analysis program
LinRegPCR was used (Ruijter et al. 2009). The target is defined as
the specific product to be measured, in this article the cDNA copy
of the miRNAs including the ligated primer.
In this article, ameasurement is defined as the act ofmeasuring the
concentration of themiRNA in a sample using qPCR. This measure-
ment results in aCq value.When themelting curve and amplification
curve are correct, the Cq value determined from the amplification
curve can be used to calculate the starting concentration (N0), which
is thus defined as the result of the qPCR measurement.
A sample is defined as the total of RNA extracted from the blood
that was drawn from the patient or control subject and reverse tran-
scribed into cDNA. From this cDNA, a small amount (usually 1 µL)
is transferred to the qPCR plate to be amplified. In this manuscript,
the cDNA equivalent to the initial amount of (mi)RNA in one well
of one plate is referred to as a “reaction.”
Cohorts for validation of the proposed pipeline
In this article, we used two large independent cohorts on circulating
miRNAs to illustrate common pitfalls during qPCR data handling
and to validate the proposed pipeline. In brief, cohort I consecutive-
ly included 834 ambulatory patients treated for heart failure (HF) in
an outpatient setting between August 2006 and June 2011. Cohort II
prospectively enrolled 1750 HF patients between 2007 and 2015.
From the latter cohort, the first 1380 patients were used for
miRNA measurement and analysis.
In the first validation, the data from both cohorts were used with
and without application of the proposed pipeline to illustrate the ef-
fect of this pipeline on the precision of the hazard ratios determined
for a set of candidate miRNA markers. To this end, we assessed the
prognostic value of 12 miRNAs on heart failure related mortality
and morbidity. In the second validation, data of cohort I were
used to determine the effect of data handling on the relation between
quartiles of hs-troponin T and miR-499a-5p expression.
qPCR measurements
Blood collection and processing
In both cohort I and II, whole-blood samples were collected by ve-
nipuncture in EDTA tubes and were centrifuged. Plasma was sepa-
rated, then aliquoted and frozen within 1 h of collection. Samples
were stored at −70°C. Samples were stored between 2006 and
2011 (cohort I) and between 2007 and 2015 (cohort II) and were
thawed for further analysis in 2014–2015.
RNA isolation
In cohort I, RNA was isolated from 500 µL plasma using the
mirVana kit (Thermofisher Scientific) according to themanufactur-
er’s instructions. The RNA pellet was collected in 100 µL RNAse free
water. In cohort II, RNA was extracted from 200 µL plasma using
750 µL TRIzol LS reagent (Invitrogen Corp.) and was incubated
for 10 min at room temperature followed by 200 µL chloroform.
The mixture was centrifuged at 12,000g for 10 min, and the aqueous
layer was transferred to a new tube. RNAwas precipitated by isopro-
panol and washed with 75% ETOH subsequently. The RNA pellet
was collected in 50 µL RNAse free water. Nucleic acid quantification
could not be performed due to the low concentration of RNA in
plasma. DNAse and RNAse treatment was omitted since previous
experiments showed no difference of miRNA expression in plasma
with and without these treatments.
de Ronde et al.
818 RNA, Vol. 23, No. 5
Reverse transcriptase of miRNAs
In both cohorts, complementary DNA was obtained from high
abundant miRNAs (miR-1254, -378a-3p, -423-5p, -320a, -345-5p,
-22-3p, -486-5p) using the miScript reverse transcription kit
(Qiagen) according to the manufacturer’s instruction. More specif-
ically, the RT reaction consisting of 7.5 μL RNA from the isolation,
0.5 µL miscript RT, and 2 µL of 5× RT Buffer was incubated at 37°C
for 60 min and at 95°C for 5 min and held at 4°C for 5 min. cDNA
was diluted in a 1:8 (cohort I) or 1:5 (cohort II) ratio using nuclease
free water.
For less abundant miRNAs (miR-133a-3p, -133b, -208a-3p,
-499a-5p, -622, -1306-5p), qScript microRNA cDNA Synthesis Kit
(Quanta BioSciences) was used, according to the manufacturer’s
protocol. Specifically, first, a poly(A) tailing reaction was performed
using 3 µL of RNA, 2 µL of poly(A) tailing Buffer (5×), 4 µL of nu-
clease-free water, and 1 µL Poly(A) polymerase. This was incubated
for 60 min at 37°C followed by 5 min on 70°C. Subsequently, 10 µL
of this poly(A) tailing reaction, 9 µL of miRNA cDNA reaction mix
and 1 µL of qscript RT were incubated for 20 min at 42°C followed
by 5min at 85°C. cDNAwas diluted in a 1:8 (cohort I) or 1:5 (cohort
II) ratio using nuclease free water. Both a nontemplate control and a
no-RT control were included in the measurement to assure that
products were not the result of genomic DNA or RNA.
Quantification and analysis of miRNA expression
by RT-qPCR
Expression levels of eachmiRNAwere quantified by RT-qPCR using
Sybr Green (Roche) and miRNA primers (Eurofins; primer se-
quences are shown in Supplemental Table 2) in a total volume of
10 µL according to the manufacturer’s instruction. This mix con-
tained 5 µL of SybrGreen dye, both 0.5 µL of forward primer and
0.5 µL of reverse primer from a 10 pmol/µL stock, 2 µL of RNase-
free water, and 2 µL of template cDNA. RT-qPCR reactions were
run in duplicates on the Light cycler 480 (Roche). The reaction mix-
ture was preincubated at 5°C for 10 sec, followed by 45 cycles of 95°C
for 10 sec, 58°C or 55°C for 20 sec (dependent on the primer char-
acter) and 72°C for 30 sec. Melting curve analysis was done by hand
and melting curves were marked as bad when the melting curve de-
viated from the positive control or showedmultiple peaks. Raw fluo-
rescence data were analyzed using LinRegPCR quantitative qPCR
data analysis software version 2014.6 (Ruijter et al. 2009). PCR effi-
ciencies were between 1.67 and 2.09 for all miRNAs. Data were nor-
malized to miR-486-5p and log10-transformed before statistical
analysis.
Hs-troponin T measurement
Hs-troponin T levels were measured (via electrochemiluminescence
immunoassay using an hs-cTnT assay and the Modular Analytics E
170 system [Roche]). The hs-cTnT assay had an analytic range of 3–
10,000 ng/L. At the 99th percentile value of 13 ng/L, the coefficient
of variation was 9%. The analytic performance of this assay has been
validated and complies with the recommendations of the ESC-
ACCFAHA-WHFGlobal Task Force for use in the diagnosis of myo-
cardial necrosis (Bassand et al. 2007). Assays were run with reagents
from lot 157123, which was unaffected by the analytical issues that
emerged with Roche hs-cTnT assays.
Multiple imputation
Invalid data were imputed using multiple imputation. Multiple
imputation is a frequently used technique in clinical research to es-
timate the missing values based on all available patient characteris-
tics. This method consists of three steps: (i) imputation, (ii) analysis,
and (iii) pooling. In the imputation step, values of the missing data
are estimated by random sampling from the distribution of the non-
missing, observed data and adjusted to the characteristics of the
sample (e.g., when imputing a missing value of the weight of a pa-
tient, taking in account the gender and length of the patient will pro-
duce a more accurate estimate). To correct for uncertainty about the
imputed value, the imputation step is repeated to create five or more
different imputed data sets. In the next step, the statistical analysis is
performed on each imputed data set separately, and in the final step,
all analysis results are pooled to create a final result. Multiple impu-
tation is incorporated in the most widely used statistical analysis
software programs such as SPSS for Windows. The exact formulas
describing this method can be found in the original work of
Rubin (1987).
Statistical analysis
ANOVAwith post hoc Student’s t-tests were used to calculate differ-
ences in miR-499a-5p expression in quartiles of hs-troponin T. F-
tests were used to test differences in variance between the different
ways of data handling in the validation experiment. Variables with
a skewed distribution, e.g., the miRNA expression levels, were log-
transformed before they were analyzed. Statistical analyses were per-
formed using SPSS for Windows Version 23. A P-value <0.05 was
considered statistically significant.
Calculations
Calculation 1. A difference of 0.5 cycles between replicates
is expected with 15% pipetting error
The basic equation for PCR kinetics (Ruijter et al. 2009) can be re-
written to calculate the Cq, the number of cycles needed to reach the
threshold,
Cq = logNq − logN0
log E
, (1)
from the starting concentration (N0), the quantification threshold
(Nq), and the PCR efficiency (E), defined as the fold increase per cy-
cle. Assuming that N0 follows a normal distribution, the effect of a
pipetting error (P), randomly up or down, on the starting concen-
tration N0(P) is
N0(P) = (1+ P) × N0. (2)
When combining Equation 1 and Equation 2, the Cq that corre-
sponds to a certain pipetting error can be calculated as
Cq(up, down) = logNq − log{(1+ P) × N0}
log E
= logNq − log(1+ P) + logN0
log E
. (3)
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The Cq range for a certain pipetting error P is then given by





Note that this range is dependent on the PCR efficiency but inde-
pendent of Nq and N0. Using Equation 4, with mean PCR efficiency
of 1.9, a Cq range of 0.5 is reached with 15% pipetting error (Fig.
2A).
Calculation 2: Expected Cq range between replicates
It is commonly accepted that with an input of 10 template copies in
the reaction and a PCR efficiency between 1.8 and 2, a Cq value of
approximately 35 will be observed (Shipley 2013, see also calcula-
tions 3).
By definition, the relation between the number of template copies
in a reaction and the observed Cq value is given by the basic equation
for PCR kinetics:
Nq = N × ECq , (5)
with the quantification threshold (Nq) and a given PCR efficiency
(E). However, according to the above rule of thumb, for 10 copies
of template Equation 5 can be written as
Nq = 10× E(35). (6)
Combining those equations shows that for an observed Cq value the
number of template copies (N) pipetted into the PCR reaction can
be approximated with
N = 10× E(35−Cq). (7)
At low concentrations (N), the actual input in the PCR reaction is
strongly subject to a Poisson sampling error during pipetting.
Using the relationship between Poisson and χ2 distributions
(Johnson et al. 1993), the 95% confidence interval of N is given by
1
2




The upper and lower limits of this interval in actual number of cop-
ies in the reaction will be observed as the lower and upper limits of
the range of Cq values. As shown in calculation 1, the basic equation
for PCR kinetics can be converted into an equation to calculate the
Cq value fromNq, E, andN0 (calculations 1, Equation 1). This equa-
tion can be extended into an equation for the difference in Cq values
(delta Cq) for 2 inputs (Nup and Nlow).
delta Cq = log(Nup) − log(Nlow)
log E
. (9)
WithNup andNlow as the upper and lower limit from Equation 8, the
delta Cq in Equation 9 then gives the width of the 95% range of the
expected Cq values for a combination of average input copy number
and PCR efficiency. Given the effect of Poisson error on sampling,
this range of Cq values should be considered as unavoidable and
thus acceptable. Table 1 and Figure 2B show this expected range
of Cq values for PCR efficiency values from 1.6 to 2.
Calculation 3. Amplification of 10 copies results in a Cq of 35
When 1 µL of a primer solution with a concentration of 1 µM is pi-
petted into the reaction this is equivalent to an amount of 1 pmol
primers in the reaction. Based on the Avogadro constant, this equals
a number of 6.022E+11 copies of primers in the reaction. Using the
basic equation for PCR kinetics (calculations 1, Equation 1), we can
calculate the number of amplicon copies in the sample after a given
number of cycles. When the reaction starts with 10 copies and the
PCR efficiency (E) is 1.9, the number of amplicon copies and the
number of remaining primer molecules become similar after 38 cy-
cles. When this happens, the competition between amplicon and
primers during the annealing step of the PCR will decrease the
PCR efficiency and the reaction will enter the plateau phase.
Competition will already start when the amplicon number reaches
one-tenth of the primer concentration, about three cycles earlier
(Gevertz et al. 2005). Therefore, this calculation also shows that
for a reaction that starts with 10 copies of template, the exponential
phase of the PCR will end at approximately 35 cycles. For other
primer concentrations and PCR efficiency values, this calculation
gives different but similar results.
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Supplemental material is available for this article.
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